Elizabeth S. Higgs - Concepedia

Author

Elizabeth S. Higgs

National Institute of Allergy and Infectious Diseases

Also Known As

Annetine C. Gelijns, E Higgs, E S Higgs, E. Higgs, E. S. Higgs, E.S. Higgs, ELIZABETH S. HIGGS, Edward Higgs, Elizabeth S. Higgs, Elizabeth Higgs

108

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health University of Minnesota University of Liberia Duke University

About

Elizabeth S. Higgs is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, immunology, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	510
2	Public Health	5	5	127
3	Education	1	1	14
4	Language Studies	1	1	165
5	Law	1	1	31

Elizabeth S. Higgs

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States* Todd W. Rice, Lewis Rubinson, Timothy M. Uyeki, Critical Care Medicine	2012	387
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia Stephen B. Kennedy, Fatorma K. Bolay, Mark Kieh, New England Journal of Medicine	2017	249
Moral Standards for Research in Developing Countries from "Reasonable Availability" to "Fair Benefits" M. El Setouhy, Tsiri Agbenyega, Francis Anto, The Hastings Center Report	2004	220
The Two‐Culture Problem: Ecological Restoration and the Integration of Knowledge Elizabeth S. Higgs Restoration Ecology Ecological RestorationCultural HeritageKnowledge ProductionLand RestorationSocial Sciences	2005	165
Paromomycin: No More Effective than Placebo for Treatment of Cryptosporidiosis in Patients with Advanced Human Immunodeficiency Virus Infection Ross G. Hewitt, Constantin T. Yiannoutsos, Elizabeth S. Higgs, Clinical Infectious Diseases	2000	143
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial Thomas L Holland, Adit A. Ginde, Roger Paredes, The Lancet Respiratory Medicine Covid-19 PandemicAntiviral TherapyClinical TrialsCovid-19 EpidemiologyMedicine	2022	124
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report Pierre-Stéphane Gsell, Anton Camacho, Adam J. Kucharski, The Lancet Infectious Diseases	2017	102
Characterization of an Asymptomatic Cohort of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Individuals Outside of Wuhan, China Yubo Wang, Yong He, Tong Jin, Clinical Infectious Diseases	2020	99
Double blind Randomized Study of Prolonged Higher-dose Oral Amoxycillin in Purulent Bronchiectasis D C Currie, N D Garbett, KN Chan, QJM Pretreatment CharacteristicsPurulent BronchiectasisAllergyAntimicrobial StewardshipAntibiotics	1990	68
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics Lisa M. LaVange, Stacey J. Adam, Judith S. Currier, Annals of Internal Medicine ImmunologyCovid-19 EpidemiologyCovid-19Master ProtocolsPreventive Medicine	2021	59

Page 1